louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06850233: The Validation of a CAD Screening Algorithm Based on Facial Photos in Community Population
Official title: The Validation of a Coronary Artery Disease Screening Algorithm Based on Facial Photos in Community Population
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Coronary Artery Disease
Keywords: Artificial Intelligence
Lead sponsor: China National Center for Cardiovascular Diseases
Sponsor class: OTHER_GOV
First posted: 2025-02-27
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: The purpose of this study is to evaluate the effectiveness of a coronary heart disease screening algorithm based on facial photos in community population.


Eligibility criteria: Inclusion Criteria:

* Community population with a pre-test probability greater than 5% for coronary artery disease

Exclusion Criteria:

* Prior percutaneous coronary intervention (PCI)
* Prior coronary artery bypass graft (CABG)
* The history of heart failure
* With artificially facial alteration (i.e. cosmetic surgery, facial trauma or make-up)
* Other situations which make patients fail to be photographed

Primary outcomes:
measure: Sensitivity of the algorithm
timeFrame: at the end of enrollment (6 months)
measure: Specificity of the algorithm
timeFrame: at the end of enrollment (6 months)
Secondary outcomes:
measure: Discriminative capabilities
timeFrame: at the end of enrollment (6 months)
measure: Positive predictive value (PPV)
timeFrame: at the end of enrollment (6 months)
measure: Negative predictive value (NPV)
timeFrame: at the end of enrollment (6 months)
measure: Diagnostic accuracy rate
timeFrame: at the end of enrollment (6 months)
Other outcomes:
Locations:
city: Zhoukou
country: China
facility: People's Road Community Health Service Center
state: Henan
Study officials:
References:
Clinical trial NCT02045433: Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer
Official title: A Phase II Study for Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer (LACC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Locally Advanced Cervical Cancer
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
First posted: 2014-01-24
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether SABR boost therapy is effective in women with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI) or genitourinary (GU) toxicity.

Detailed description: Patients enrolled in this study will receive 45 Gray (Gy) in 25 fractions of intensity modulated external beam radiation therapy + weekly cisplatinum . Following the completion of Intensity Modulated Radiation Therapy (IMRT), patients will receive 28 Gy in 4 fractions using stereotactic body radiation therapy techniques.

Eligibility criteria: Inclusion Criteria:

1 Locally Advanced stage Cervical Cancer 2. Zubrod performance status 0-2 3. Negative urine or serum pregnancy test for women of child-bearing potential 4. Agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment 5. Not a candidate for intracavitary brachytherapy

Exclusion Criteria:

1. Pregnancy
2. Concurrent untreated cancer excluding non-Melanoma skin cancer
3. Previous pelvic radiation
4. Active Inflammatory Bowel disease, Collagen vascular disease - systemic lupus erythematosus (SLE), scleroderma
5. Age \<18
6. Unable to consent for study
7. Severely immunocompromised patients ( such as Transplant , on immunosuppressive drugs)

Primary outcomes:
measure: Time Taken to Induce Primary Tumor Control
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
Study officials:
affiliation: University of Texas Southwestern Medical Center
name: Kevin Albuquerque, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01946633: Remote-controlled Capsule Endoscopy: a Feasibility Study
Official title: Remote-controlled Capsule Endoscopy: a Feasibility Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gastric Ulcer
Gastric Polyp
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2013-09-19
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The present study is a feasibility study to assess the safety and efficacy of wireless capsule endoscope and compare the data obtained with those obtained by using a conventional esophagogastroduodenoscopy.

The product was developed and manufacture in China.(the NaviCam. AKC-1.China)


Eligibility criteria: Inclusion Criteria:

* upper abdominal symptoms (≥1 year )
* surveillance gastroscopy for known gastric ulcer or polyps
* history of gastric ulcer or polyps （≤1w）at Nanfang Hospital were enrolled.

Exclusion Criteria:

* dysphagia
* suspected or documented digestive tract malformation ,obstruction, strictures or fistula
* acute upper GI bleeding, acute enteritis, acute ischemia disease
* history of abdominal operations
* impaired renal function, congestive heart failure
* patients with critical condition or mental illness
* patients with, known allergy to polymer material or antifoam agent
* patients with cardiac pacemakers or other implanted electromedical devices，magnetic resonance imaging ( mri) examination in 7 days
* pregnancy

Primary outcomes:
measure: the percentage of complete visualization of anatomic landmarks
timeFrame: 2 year
measure: examination time and the percentage of abnormal finding
timeFrame: 2 year
Secondary outcomes:
measure: adverse effect
timeFrame: 2 year
measure: Acceptability
timeFrame: 2 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Departement of Gastroenterology, Nanfang Hospital, Southern Medical University
state: Guangdong
Study officials:
References:
citation: Keller J, Fibbe C, Volke F, Gerber J, Mosse AC, Reimann-Zawadzki M, Rabinovitz E, Layer P, Schmitt D, Andresen V, Rosien U, Swain P. Inspection of the human stomach using remote-controlled capsule endoscopy: a feasibility study in healthy volunteers (with videos). Gastrointest Endosc. 2011 Jan;73(1):22-8. doi: 10.1016/j.gie.2010.08.053. Epub 2010 Nov 9.
Clinical trial NCT06694233: Improving Aspirin Prescription Rates in Outpatient Clinic
Official title: Aspirin Prescription For Moderate- and High-Risk Obstetric Population in Outpatient Clnic; A Quality Improvement Project.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Low Birth Weight
Small for Gestational Age (SGA)
Preeclampsia (PE)
Prevention &Amp; Control
Keywords: Aspirin
Preeclampsia
obstetric
risk population
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-11-19
Enrollment: 300
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Moderate- and high- risk obstetric population

Brief summary: Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies.

Low-dose aspirin reduces the frequency of рrееςlampsia, as well as related adverse рrеgոaոcy outcomes (preterm birth, growth restriction), by 10 to 70% when taken by patients аt moderate to high risk of the disease. It has an excellent maternal/fetal safety profile. Thus, it is a reasonable preventive strategy for these patients.

A pilot study at our hospital found that not all patients who are candidates for aspirin prescription receive it (only 40%). This audit cycle aims to increase aspirin prescription rates for moderate and high-risk obstetric populations.


Eligibility criteria: Inclusion Criteria:

Women at high risk are those with any of the following:

1. hypertensive disease during a previous pregnancy
2. chronic kidney disease
3. autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome
4. type 1 or type 2 diabetes
5. chronic hypertension.

Women with more than one moderate risk factor, such as are:

1. nulliparity
2. age 40 years or older
3. pregnancy interval of more than 10 years
4. body mass index (BMI) of 35 kg/m2 or more at first visit
5. family history of pre-eclampsia
6. multi-fetal pregnancy.

Exclusion Criteria:

* None. All eligible candidates will be included.

Primary outcomes:
measure: Aspirin prescription
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
city: Hadiya
country: Kuwait
facility: Adan hospital
state: Ahmadi
Study officials:
References:
citation: Singh N, Shuman S, Chiofalo J, Cabrera M, Smith A. Missed opportunities in aspirin prescribing for preeclampsia prevention. BMC Pregnancy Childbirth. 2023 Oct 7;23(1):717. doi: 10.1186/s12884-023-06039-w.
citation: Kumar NR, Speedy SE, Song J, Welty LJ, Cavens AD. Quality Improvement Initiative for Aspirin Screening and Prescription Rates for Preeclampsia Prevention in an Outpatient Obstetric Clinic. Am J Perinatol. 2024 May;41(S 01):e917-e921. doi: 10.1055/s-0042-1759705. Epub 2022 Dec 30.
Clinical trial NCT02334033: Cystatin C and Uncontrolled Hypertension
Official title: Cystatin C and Uncontrolled Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uncontrolled Hypertension
Keywords: hypertension
blood pressure
cystatin C
real-life
kidney
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2015-01-08
Enrollment: 903
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults residing in both rural and urban communities

Brief summary: Hypertension is an underdiagnosed and undertreated disease in real-life. Blood pressure and kidney functions are known to be closely related. Increased serum level of Cystatin C, a sensitive biomarker for renal function, seems to predict adverse cardiovascular events. The investigators aimed to evaluate the predictive value of serum Cystatin C for control of hypertension in a community-based study.


Eligibility criteria: Inclusion Criteria:

* Individuals who accept to participate to the survey
* \> 18 years

Exclusion Criteria:

* Individuals who are not able to complete the questionnaire
* Individuals who didn't give informed consent

Primary outcomes:
measure: The prevalence of uncontrolled hypertension
timeFrame: At subject enrollment
Secondary outcomes:
measure: The value of cystatin C to determine uncontrolled hypertension
timeFrame: At subject enrollment
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara University School Of Medicine, Department of Cardiology
Study officials:
References:
Clinical trial NCT00455351: Vorinostat and Palliative Radiotherapy
Official title: Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pelvic Cancer
Radiotherapy
Keywords: Palliative treatment
Max. tolerable dose
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2007-04-03
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase I study. Side-effects when combined with standard palliative radiotherapy.


Eligibility criteria: Inclusion Criteria:

* Pelvic malignancy
* Palliative radiation treatment planed
* ECOG \<3
* Age\>18 years

Exclusion Criteria:

* Previous pelvic radiotherapy
* Uncontrolled diarrhea
* Insulin-dependent diabetes mellitus
* BMI\<18.5

Primary outcomes:
measure: DLT
timeFrame: continously
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: The Norwegian Radium Hospital
Study officials:
affiliation: Norwegian Radium Hospital
name: Sigbjørn Smeland, MD,PhD
role: STUDY_DIRECTOR
References:
citation: Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6.
citation: Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol. 2011 Apr 8;6:33. doi: 10.1186/1748-717X-6-33.
Clinical trial NCT03779451: Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa
Official title: Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate for Prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women With Placenta Previa: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Placenta Previa
Keywords: cesarean section
placenta previa
antepartum hemorrhage
vaginal progesterone
17-Alpha-Hydroxyprogesterone Caproate
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2018-12-19
Enrollment: 400
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A randomized controlled study
Primary purpose: PREVENTION

Brief summary: Purpose to evaluate the effects of Vaginal Progesterone versus 17-Alpha-Hydroxyprogesterone Caproate for prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women with Placenta Previa

Detailed description: The study will be a randomized open-label clinical trial conducted at a tertiary university hospital outpatient clinic and some private settings at Aswan governorate, Egypt, between January 2019 and March 2022. The authors will include women who asymptomatic pregnant women with a diagnosed placenta previa at 26-28 weeks gestation. They will be randomized into three groups: group I (vaginal progesterone suppositories ), group II (received an intramuscular dose of 250 mg 17-alpha-Hydroxyprogesterone caproate(17-OHPC) once a week) and group III(control group). In each group, Follow-up visits were performed every week then admission was done at 36 weeks at our university hospital. Scheduled caesarian section was done at completed 37 weeks unless otherwise required.

Eligibility criteria: Inclusion Criteria:

* Gestational age 26-28 weeks of gestation.
* Definite and reliable diagnosis of placenta previa (defined as the presence of a placenta within 2 cm of the internal os), using a transvaginal ultrasound scan

Exclusion Criteria:

* Multiple pregnancies.
* Women at high risk of preterm labor e.g. history of spontaneous preterm labor or preterm prelabour rupture of the membranes (PPROM).
* Severe antepartum hemorrhage and/or hemodynamic instability that necessitates urgent -intervention and delivery.
* Women who have been maintained on progestin therapy since early pregnancy for whatever reason.

Primary outcomes:
measure: number of patient delivered before 37 weeks
timeFrame: 2 month
Secondary outcomes:
measure: number of episodes of antepartum hemorrhage
timeFrame: 2 month
measure: Hospital admission for significant antepartum hemorrhage
timeFrame: 2 month
measure: Neonatal Birth weight
timeFrame: one hours post operative
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University
Study officials:
affiliation: Aswan University Hospital
name: hany f sallam, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03410251: Long- Term Follow-up of Extraction Socket Management
Official title: Long- Term Follow-up of Extraction Socket Management : Clinical Outcomes and Hard Tissue Changes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tooth Loss
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2018-01-25
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients were recruited from the Department of Periodontology and Oral Surgery of the University of Liège, Belgium.

Brief summary: Twenty-nine patients needing single tooth replacement in aesthetic area were treated by extraction and socket preservation with saddle connective tissue graft between September 2009 and February 2012. Computed Tomography scan were taken at baseline just after the surgery and 3 months later. Long- term evaluation of this particular socket management procedure was evaluated by recalling successfully seventeen of theses patients in June 2016. At this time, a clinical and radiographical consultation was done and Cone Beam CT was taken. Horizontal and vertical bone dimensional changes were then assessed thanks to 3D imaging analysis and esthetic and implants outcomes were evaluated.


Eligibility criteria: Inclusion Criteria:

* Good general health (ASA 1, 2)
* Controlled periodontitis
* \>18 years of age or signed consent by the parents
* Smoking history of\<10 cigarettes per day
* Signed informed consent.

Exclusion Criteria:

* Pregnancy or lactation
* Concurrent participation in another trial
* Bone disease or the use of medications that interfered with bone metabolism
* History of head and neck radio- therapy
* Presence of dehiscence or fenestration on bone wall of the socket.

Primary outcomes:
measure: Changes from Baseline Alveolar bone remodeling to 3 months and 6 year: horizontal measurements (based on CBCT, in mm)
timeFrame: Baseline, 3 months, 6 years
measure: Changes from Baseline Alveolar bone remodeling to 3 months and 6 year : vertical measurements (based on CBCT, in mm)
timeFrame: Baseline, 3 months, 6 years
Secondary outcomes:
measure: Esthetic outcomes (PES questionnaire)
timeFrame: Approximatively 6 years
measure: Esthetic outcomes (VAS questionnaire)
timeFrame: Approximatively 6 years
measure: Implant survival rate (based on criteria of Buser et al., 1990)
timeFrame: Approximatively 6 years
measure: Peri-implant bone levels (based on periapical radiography, in mm)
timeFrame: Approximatively 6 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01577251: The Radiation Oncology Registry and Biosample Repository
Official title: Registry and Biosample Repository
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neoplasia
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2012-04-13
Enrollment: 8000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Anyone age 18 and above with a cancer and/or benign tumor diagnosis undergoing radiotherapy

Brief summary: The goal of this study is to establish a registry and biosample repository (defined as blood, urine, and tumor specimens) in patients with a cancer and/or benign tumor diagnosis undergoing radiotherapy.


Eligibility criteria: * Anyone age 18 and above with a cancer and/or benign tumor diagnosis undergoing radiotherapy
* Able to sign consent

Primary outcomes:
measure: Health Assessments
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Moorestown
country: United States
facility: Virtua Samson Cancer Center
state: New Jersey
city: Voorhees
country: United States
facility: Virtua Health & Wellness Center
state: New Jersey
city: Lancaster
country: United States
facility: Lancaster General Hospital
state: Pennsylvania
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Jay Dorsey, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02695251: AGE - Functional Reserve
Official title: Renal Hemodynamic, Functional and Metabolic Changes After AGEs (Advanced Glycation End Products) Load by Positron Emission Tomography (PET) and Blood Oxygen Level-Dependent (BOLD) - MRI. The AGE- Functional Reserve Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kidney Function Tests
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-03-01
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Renal functional reserve is defined as the glomerular hyper filtration induced by a protein load. Renal blood flow and Glomerular Filtration Rate (GFR) increase in response to a protein load. Renal functional reserve loss is associated with a persistent hyper filtration state, seen in first stages of diabetic nephropathy, leading to progression of Chronic Kidney Disease (CKD). This observation has lead to larger clinical studies that demonstrated the positive effects of protein restriction on kidney function, and allowed the scientific community to recommend low proteins diet (less than 0.8 g / kg/ day) to prevent CKD progression. Nevertheless, the precise mechanisms responsible for kidney hemodynamic and metabolic changes induced by a protein load, are debated. Uribarri et al have suggested that renal hemodynamic changes induced by a protein load are mainly due to the Advanced Glycation End Products (AGEs) content. Indeed, initial studies experimental conditions leading to the demonstration of renal functional reserve (amino acid or protein perfusion or cooked meat), were in fact responsible for an AGEs load, based on recent published data.

The aim of this study is to determine whether AGEs alone or proteins in general are responsible for the mobilization of renal functional reserve, leading to the progression of CKD.


Eligibility criteria: Inclusion Criteria:

* Healthy males subjects
* age between 18 and 30 years old

Exclusion Criteria:

* Kidney disease
* Diabetes
* Obesity
* Hypertension
* Non Steroidal Anti Inflammatory Drug treatment (NSAIDS)
* MRI Contra indications
* Myeloma
* High basal Radiation exposure : more than 1 milliSievert (mSv) in the last 6 months

Primary outcomes:
measure: Renal Blood Flow
timeFrame: 120 minutes after meal
Secondary outcomes:
measure: renal oxygen content
timeFrame: 120 minutes after meal
measure: renal oxidative metabolism
timeFrame: 120 minutes after meal
Other outcomes:
Locations:
city: Lyon
country: France
facility: Service de Néphrologie - Hôpital Edouard Herriot
Study officials:
affiliation: Hospices Civils de Lyon
name: Laurent JUILLARD, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Normand G, Lemoine S, Villien M, Le Bars D, Merida I, Irace Z, Troalen T, Costes N, Juillard L. AGE Content of a Protein Load Is Responsible for Renal Performances: A Pilot Study. Diabetes Care. 2018 Jun;41(6):1292-1294. doi: 10.2337/dc18-0131. Epub 2018 Apr 2.